Stockholm - Delayed Quote SEK

LIDDS AB (publ) (LIDDS.ST)

Compare
0.1045 -0.0010 (-0.95%)
At close: December 20 at 5:29:55 PM GMT+1

Key Executives

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mats Wiking CEO, CFO & Head of IR -- -- 1969
Ms. Monica Wallter Senior Advisor 1.87M -- 1956
Ms. Kia Bengtsson Head of Clinical Development -- -- 1969
Dr. Roger Belusa Chief Medical Officer -- -- --

LIDDS AB (publ)

Virdings allé 32B
Uppsala, 754 50
Sweden
https://www.liddspharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
1

Description

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. The company's oncology pipeline in clinical development includes Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug that binds and blocks androgen receptors; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological conditions, such as breast cancer, head and neck cancer, and prostate cancer; and Nanoimod, a NanoZolid-formulated agatolimod, which is a toll-like receptor 9 (TLR9) agonist. The company was founded in 2003 and is based in Uppsala, Sweden.

Corporate Governance

LIDDS AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 22, 2025 at 10:59 AM UTC

LIDDS AB (publ) Earnings Date

Recent Events

Related Tickers

NANECH.ST NanoEcho AB
0.1580
+21.54%
 
QUIA.ST Quia Pharma AB (publ)
0.0172
+3.61%
 
COMBI.ST CombiGene AB (publ)
2.7200
+5.43%
 
DIABIO.ST Diagonal Bio AB (publ)
0.0258
+5.31%
 
PCIB.OL PCI Biotech Holding ASA
1.3200
-7.04%
 
ZICC.ST Ziccum AB (publ)
0.3830
-6.36%
 
CRNA.OL Circio Holding ASA
0.7080
-3.28%
 
ULTI.OL Ultimovacs ASA
2.5500
-3.77%
 
FLUI.ST Fluicell AB (publ)
0.0412
-1.90%
 
ISOFOL.ST Isofol Medical AB (publ)
2.4050
-3.80%